BLA 761079 · Biomarin Pharm
Palynziq
Pegvaliase-Pqpz · Injection · Phenylalanine Metabolizing Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 24, 2018
Approved uses
5
Original approval plus efficacy supplements
Registered trials
11
4 Phase 3, 5 recruiting
FAERS reports
8,518
1,340 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS Anaphylaxis has been reported after administration of PALYNZIQ and may occur at any time during treatment [see Warnings and Precautions (5.1) ] . Administer the initial dose of PALYNZIQ under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to self-injection, confirm patient competency with self-administration, and patient's and observer's (if applicable) ability to recognize signs and symptoms of anaphylaxis and administer epinephrine, if needed [see Dosage and Administration (2.5) ] . Consider having an adult observer for patients who may need assistance in recognizing and managing anaphylaxis during PALYNZIQ treatment. If an adult observer is needed, the observer should be present during and for at least 60 minutes after PALYNZIQ administration, should be able...
What it is approved for
From the label in effect Mar 2, 2026.
PALYNZIQ is indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. ( 1 )
Mechanism: Pegvaliase-pqpz is a PEGylated phenylalanine ammonia lyase (PAL) enzyme that converts phenylalanine to ammonia and trans -cinnamic acid. It substitutes for the deficient phenylalanine hydroxylase (PAH) enzyme activity in patients with PKU and reduces blood phenylalanine concentrations.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2026 Supplement 31 · Efficacy · priority review OrphanLetterLabel
- Oct 6, 2020 Supplement 6 · Efficacy OrphanLetter
- Oct 6, 2020 Supplement 7 · Efficacy OrphanLetter
- Oct 6, 2020 Supplement 5 · Efficacy OrphanLetterLabel
- May 24, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- PALYNZIQ · PEGVALIASE-PQPZ 20MG/ML · INJECTABLE, INJECTION · Prescription
- PALYNZIQ · PEGVALIASE-PQPZ 2.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
- PALYNZIQ · PEGVALIASE-PQPZ 10MG/0.5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegvaliase" as an intervention, any sponsor and status, largest first.
- An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165Pivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01819727 · 261 participants · Start May 2013 · Primary completion Nov 25, 2015
Drug: BMN 165 · For: Phenylketonuria
Sites: La Jolla, California; Oakland, California; Aurora, Colorado · 31 sites in all
- Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKUPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01889862 · 215 participants · Start Jul 29, 2013 · Primary completion Jan 13, 2016
Drug: BMN165 20mg/day; BMN165 40mg/day and 1 more · For: Phenylketonuria (PKU)
Sites: La Jolla, California; Oakland, California; Aurora, Colorado · 29 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00924703 · 68 participants · Start Jan 13, 2010 · Primary completion Jan 31, 2019
Drug: rAvPAL-PEG · For: Phenylketonuria
Sites: Aurora, Colorado; Gainesville, Florida; Chicago, Illinois · 14 sites in all
- Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With PhenylketonuriaPivotal-lookingActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT05270837 · 55 participants · Start Jun 17, 2022 · Primary completion Jan 14, 2025
Drug: Pegvaliase · For: Phenylketonuria (PKU)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Aurora, Colorado · 16 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00925054 · 40 participants · Start Sep 2009 · Primary completion Jun 2015
Drug: rAvPAL-PEG 0.001 mg/kg; rAvPAL-PEG 0.003 mg/kg and 3 more · For: Phenylketonuria
Sites: Aurora, Colorado; Decatur, Georgia; Chicago, Illinois · 11 sites in all
- Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKUPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03694353 · 37 participants · Start Sep 13, 2018 · Primary completion Jan 13, 2021
Drug: Pegvaliase · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Chicago, Illinois · 17 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00634660 · 25 participants · Start May 2008 · Primary completion Apr 2009
Drug: rAvPAL-PEG · For: Phenylketonuria
Sites: Chicago, Illinois; Minneapolis, Minnesota; St Louis, Missouri · 8 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01560286 · 24 participants · Start May 2012 · Primary completion Sep 2013
Drug: BMN 165 (rAvPAL-PEG) · For: Phenylketonuria
Sites: Aurora, Colorado; Gainesville, Florida; Boston, Massachusetts · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- arthralgia1,463
- injection site reaction957
- injection site erythema794
- injection site swelling584
- rash533
- urticaria523
- headache461
- injection site pain448
- injection site pruritus389
- fatigue386
- pruritus359
- hypersensitivity357
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 156 |
| 2019 | 1,038 |
| 2020 | 1,207 |
| 2021 | 1,114 |
| 2022 | 860 |
| 2023 | 1,027 |
| 2024 | 1,148 |
| 2025 | 1,082 |
| 2026 | 886 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Palynziq (PEGvaliase-Pqpz)
2024 spending
$24.7M
Beneficiaries
109
958 claims
Per beneficiary
$226,254
$796.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,917,017 |
| 2021 | $15,293,515 |
| 2022 | $15,703,046 |
| 2023 | $20,307,239 |
| 2024 | $24,661,658 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term management strategies for pegvaliase use in phenylketonuria: Lessons learned from the phase-3 PRISM open-label extension study.
Harding CO, Whitehall KB, Lilienstein J, et al. · Genet Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Pegvaliase treatment normalizes blood neurotransmitter metabolites in adults with phenylketonuria.
Sigg MA, Wilson C, Clague GE, et al. · Mol Genet Metab 2024 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.
Aryal M, Lau K, Boyer R, et al. · Mol Genet Metab 2021 · Clinical Trial, Phase III, Multicenter Study
- Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
Zori R, Ahring K, Burton B, et al. · Mol Genet Metab 2019 · Clinical Trial, Comparative Study
- Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
Ishige M, Ito T, Hamazaki T, et al. · Mol Genet Metab 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
Burton BK, Longo N, Vockley J, et al. · Mol Genet Metab 2020 · Clinical Trial, Phase II, Multicenter Study
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.